Citation Information: JCI Insight. 2020. https://doi.org/10.1172/jci.insight.137753.
Abstract
Noonan syndrome with multiple lentigines (NSML) is a rare autosomal dominant disorder that presents with cardio-cutaneous-craniofacial defects. Hypertrophic cardiomyopathy (HCM) represents the major life-threatening presentation in NSML. Mutations in the PTPN11 gene that encodes for the protein tyrosine phosphatase (PTP), SHP2, represents the predominant cause of HCM in NSML. NSML-associated PTPN11 mutations renders SHP2 catalytically inactive with an “open” conformation. NSML-associated PTPN11 mutations cause hypertyrosyl phosphorylation of the transmembrane glycoprotein, protein zero-related (PZR) resulting in increased SHP2 binding. Here we show that NSML mice harboring a tyrosyl phosphorylation-defective mutant of PZR (NSML/PZRY242F) that is defective for SHP2 binding fail to develop HCM. Enhanced AKT/S6K signaling in heart lysates of NSML mice was reversed in NSML/PZRY242F mice demonstrating that PZR/SHP2 interactions promote aberrant AKT/S6K activity in NSML. Enhanced PZR tyrosyl phosphorylation in the hearts of NSML mice was found to drive myocardial fibrosis by engaging a Src/NFkB pathway resulting in increased activation of interleukin-6 (IL6). Increased expression of IL6 in the hearts of NSML mice was reversed in NSML/PZRY242F mice and PZRY242F mutant fibroblasts were defective for IL6 secretion and STAT3-mediated fibrogenesis. These results demonstrate that NSML-associated PTPN11 mutations that induce PZR hypertyrosyl phosphorylation trigger pathophysiological signaling that promotes HCM and cardiac fibrosis.
Authors
Jae-Sung Yi, Sravan K. Perla, Liz E. Enyenihi, Anton M. Bennett
